A detailed history of Virtus ETF Advisers LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,773 shares of FDMT stock, worth $29,391. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,773
Previous 3,709 1.73%
Holding current value
$29,391
Previous $77,000 48.05%
% of portfolio
0.02%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.81 - $27.22 $691 - $1,742
64 Added 1.73%
3,773 $40,000
Q2 2024

Aug 14, 2024

SELL
$20.93 - $30.01 $31,520 - $45,195
-1,506 Reduced 28.88%
3,709 $77,000
Q1 2024

May 15, 2024

SELL
$17.03 - $35.87 $6,113 - $12,877
-359 Reduced 6.44%
5,215 $166,000
Q4 2023

Feb 15, 2024

BUY
$9.76 - $21.25 $10,687 - $23,268
1,095 Added 24.45%
5,574 $112,000
Q3 2023

Nov 07, 2023

SELL
$12.64 - $19.76 $5,612 - $8,773
-444 Reduced 9.02%
4,479 $57,000
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $11,870 - $18,212
783 Added 18.91%
4,923 $88,000
Q1 2023

May 15, 2023

SELL
$15.45 - $23.19 $24,580 - $36,895
-1,591 Reduced 27.76%
4,140 $71,000
Q4 2022

Feb 14, 2023

BUY
$6.85 - $25.46 $39,257 - $145,911
5,731 New
5,731 $127,000
Q2 2022

Aug 12, 2022

SELL
$5.68 - $15.99 $43,639 - $122,851
-7,683 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$13.16 - $22.64 $6,014 - $10,346
-457 Reduced 5.61%
7,683 $116,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $17,271 - $29,086
883 Added 12.17%
8,140 $179,000
Q3 2021

Nov 15, 2021

SELL
$22.73 - $36.04 $8,751 - $13,875
-385 Reduced 5.04%
7,257 $196,000
Q2 2021

Aug 10, 2021

BUY
$22.2 - $42.29 $169,652 - $323,180
7,642 New
7,642 $184,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $252M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.